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Copy number variants (CNVs) are associated with psychiatric conditions in clinical populations. The
relationship between rare CNV burden and neuropsychiatric traits in young, general populations is
underexplored. A total of 6,807 children from the Avon Longitudinal Study of Parents and Children
(ALSPAC) were studied. CNVs were inferred from single nucleotide polymorphism-array data using
PennCNV. After excluding children with known candidate CNVs for schizophrenia (SCZ), rare (<1%)
CNV burden (total number of genes affected by CNVs, total length of CNVs, and largest CNV carried)
was analyzed in relation to: psychotic experiences (PEs) and anxiety/depression in adolescence;
autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD), ASD and ADHD
traits, and cognitive measures during childhood. Outcomes were also assessed in relation to known
SCZ CNVs. The number of genes affected by rare CNVs was associated with a continuous measure
of ASD: the standardized mean difference [SMD] per gene affected was increased by 0.018 [95%CI
0.011,0.025], p53e-07 for duplications and by 0.021 [95%CI 0.010, 0.032], p51e-04 for deletions.
In line with our published results on educational attainment in ALSPAC, intelligence quotient (IQ) was
associated with CNV burden: the SMD per gene affected was 20.017 [95%CI 20.025, 20.008]
p51e-04 for duplications and20.023 [95%CI20.037,20.009], p5 .002 for deletions. Associations
were also observed for measures of coherence, attention, memory, and social cognition. SCZ-
associated deletions were associated with IQ (SMD: 20.617 [95%CI 20.936, 20.298], p52e-04),
but not with PEs or other traits.We found that rare CNV burden and known SCZ candidate CNVs are
associatedwith neuropsychiatric phenotypes in a nonclinically ascertained sample of young people.
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1 | INTRODUCTION
The heritability of neuropsychiatric traits is substantial (Polderman
et al., 2015): twin studies estimate the heritability of schizophrenia
(SCZ) to be 0.81 (95%CI 0.73, 0.90) (Sullivan Sullivan, Kendler, & Neale,
2003), with estimates of a similar magnitude (0.75–0.80) for autism
spectrum disorder (ASD) (Ronald & Hoekstra, 2011), intelligence quo-
tient (IQ) (Plomin & Deary, 2015), bipolar disorder (BPD) (Sullivan, Daly,
& O’Donovan, 2012), and attention-deficit hyperactivity disorder
(ADHD) (Faraone et al., 2015). Other disorders, such as major
depressive disorder (MDD) may be less heritable (0.37, [95%CI 0.31,
0.42]) (Sullivan, Neale, & Kendler, 2000), although there is variance in
estimates by subtype (e.g., recurrence, age of onset) (Ripke et al.,
2013). While the magnitude of heritability estimates varies by the
methodology used (e.g., population-based designs estimate lower herit-
ability of SCZ (0.67 [95%CI 0.64, 0.71]) (Samson & Wong, 2015; Wray
& Gottesman, 2012) and ASD (0.50 [95%CI 0.45–0.56]) (Sandin et al.,
2014), respectively, in population-based designs) (Sullivan et al., 2003),
genetic factors are undoubtedly important contributors to variance
observed in neuropsychiatric traits.
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It is known that rare copy number variants (CNVs) contribute to
the etiology of many neuropsychiatric phenotypes, including (but not
limited to) SCZ (Grozeva et al., 2010; Kirov, 2015; Kirov et al., 2009,
2012; Morrow, 2010; Stone et al., 2008), ASDs (Ching et al., 2010;
Glessner et al., 2009; Morrow, 2010; Sebat et al., 2007; Urraca et al.,
2013), ADHD (Martin et al., 2014; Williams et al., 2010), cognitive abil-
ity (Guffanti et al., 2013), and educational attainment (Männik et al.,
2015). A useful working definition of CNVs is that they are genomic
regions (often classified as >1 kb in length) that are duplicated or
deleted in comparison to a reference genome (Redon et al., 2006).
Compared to phenotype associations with single nucleotide variants,
CNVs tend to confer larger effects (Girirajan et al., 2011; Thapar &
Cooper, 2013). A recent survey of rare CNVs in 60,000 human exomes
found that 70% of individuals carry at least one rare, genic CNV, and
that on average, copy number gains are more common than losses
(Ruderfer et al., 2016).
There is substantial pleiotropy between many of these psychiatric
phenotypes: in a study of five disorders (SCZ, BPD, MDD, ASD,
ADHD), consistent genetic correlations (rG) estimated from single
nucleotide polymorphism (SNP) data by both restricted maximum likeli-
hood) and linkage disequilibrium-score regression were found, including
the highest rG of 0.79 for SCZ and BPD (Bulik-Sullivan et al., 2015).
This same study observed more modest (yet still substantial) rG values
of 0.14 and 0.23 for SCZ/ASD and SCZ/ADHD. Cross-phenotypic
overlap is also observed with CNV associations: perhaps the strongest
evidence comes from CNVs robustly associated with SCZ, which are
also associated with developmental delay, ASD, and congenital malfor-
mations (Kirov et al., 2014; O’Donovan & Owen, 2016). CNVs impli-
cated in ASD and SCZ have also shown enrichment in children with
ADHD (Williams et al., 2010).
While many studies have examined the association of genetic varia-
tion in relation to clinical psychiatric diagnoses, genetic association stud-
ies of neuropsychiatric traits in population-based samples of younger
individuals (i.e., prior to the age of onset of many psychiatric conditions)
are less numerous. Within the Avon Longitudinal Study of Parents and
Children (ALSPAC) cohort, the use of common genetic variation has
provided insight into the shared etiology of psychiatric disorders and
traits in the general population. Salient examples include: the genetic
correlation between ADHD traits and ADHD diagnosis (Stergiakouli
et al., 2015), the shared genetic risk of ASD and population-level var-
iance in social and communication ability (Robinson et al., 2016), and
the association of a polygenic risk score for SCZ with adolescent meas-
ures of negative symptoms and anxiety (but not psychotic experiences
[PEs]) (Jones et al., 2016) SCZ also shows a strong genetic correlation
with ADHD in ALSPAC (Nivard et al., 2017). Concerning rarer variation,
in a large study of the burden of rare CNVs and cognitive phenotypes
in unselected populations, including ALSPAC, we previously found that
these variants were negatively associated with educational attainment
(Männik et al., 2015). In UK Biobank, carriers of known pathogenic
CNVs have also been observed to have reduced cognitive performance
(Kendall et al., 2016). However, associations between rare CNVs and
other neuropsychiatric traits are underexplored.
Using data from a young, general population sample (ALSPAC), we
first sought to study the burden of large, rare CNVs on a range of neu-
ropsychiatric phenotypes, including ADHD, ASD, depression, anxiety,
PEs, and neurocognition. The secondary objective was to test the rela-
tionship of known SCZ candidate CNVs with the traits studied.
2 | MATERIALS AND METHODS
2.1 | Cohort details
The ALSPAC is a prospective cohort of mothers and children. Between
1991 and 1992, 14,541 women living in the former county of Avon,
UK were recruited during pregnancy, of whom 13,761 were enrolled
into the study. Participants have been followed up longitudinally since
recruitment. Further details are available in the cohort profile papers
(Boyd et al., 2013; Fraser et al., 2013), and the study website contains
details of available data through a fully searchable data dictionary:
http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/
Ethical approval for the study was obtained from the ALSPAC
Ethics and Law Committee and the Local Research Ethics Committees.
2.2 | Genotyping and quality control
The ALSPAC children were genotyped on the Illumina HumanHap550-
Quad platform, by the Wellcome Trust Sanger Institute, Cambridge,
UK, and the Laboratory Corporation of America, Burlington, NC, using
support from 23andMe. Samples were removed if there were gender
mismatches, disproportionate heterozygosity, >3% missingness, and
insufficient sample replication (IBD <0.8). A total of 8,365 participants
who were unrelated at an IBD of >0.125 were included, and all were
of European ancestry (non-Europeans were removed after multidimen-
sional scaling, and comparison with the HapMap CEU population).
Genomic locations described in this paper relate to NCBI build 37/
hg19, unless otherwise stated.
2.3 | CNV calling
CNVs were called on 7,572 participants using PennCNV (Wang et al.,
2007), and the default libraries provided with the package for the
HumanHap550 array (Hidden Markov Model [hh550.hmm] and Popu-
lation Frequency of B Allele [hh550.hg18.pfb] files). Log R ratio (LRR)
and B Allele Frequency were derived from Illumina Final Report files
using a custom Python script (available at: https://github.com/
MRCIEU/IlluminaFinalRep_LRRBAF).
After calling, all 7,572 subjects had at least one CNV (with
150,657 CNVs among this group in total). These individuals were
retained for quality control (QC). Figure 1 shows a flowchart of the QC
and filtering process for the CNV data. First, CNVs were merged if
they were separated by a gap less than half of their combined length
using the “clean_cnv.pl” script provided within PennCNV (Wang et al.,
2007). Individuals were then dropped from the analysis if they had
>30 CNV calls (Nag et al., 2013), if they had a LRR standard deviation
(SD) of >0.3, a B Allele Frequency drift (BAF drift) of >0.002, or an
absolute waviness factor of >0.05. The filter values for LRR SD, BAF
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drift and waviness factor are all as recommended by PennCNV devel-
opers (Wang et al., 2007). Next, CNVs were removed from the analysis
if at least 50% of the CNV call overlapped with telomeric, centromeric,
or immunoglobulin regions (see Supporting Information Notes 1, 2 and
3 for details of coordinates). Known regions of segmental duplications
were also removed (as downloaded from the UCSC Genome Browser
[https://genome.ucsc.edu/] [Kent et al., 2002]). CNVs were removed if
they fulfilled any of the following criteria: if they spanned <10 probes,
were <5 kb or >5 Mb in length, or had a confidence score of <10.
Finally, those CNVs that had a density of less than one probe per 20
kb were removed.
After QC, there were 22,037 CNVs and 6,913 subjects (311 of
whom had no CNVs after QC). PLINK was used to identify CNVs with
a sample frequency of <1% (using PLINK flags –cnv-freq-exclude-
above 69 [as 6,913 individuals passed QC], –cnv-overlap 0.5) (Purcell
et al., 2007; Tansey et al., 2016).
After filtering for those with no outcome data, but complete con-
founder data, 21,678 CNVs remained (11,750 with a frequency <1%),
split among 6,807 subjects. CNVs were mapped to genes using the
“refGene” database, also downloaded from UCSC Genome Browser
(Kent et al., 2002).
2.4 | Phenotypes
Descriptive statistics of each variable, as well as the numbers in the risk
group (or means/medians for continuous variables) are summarized in
Table 1. Correlations between phenotypes are shown in Figure 2. See
Supporting Information Methods for extended details of the pheno-
types. Diagnoses were studied as binary variables. Traits were studied
continuously where possible, and dichotomized (defining a risk
group as close to 10% as possible) if skewness prohibited simple
transformation.
2.4.1 | Psychiatric traits and diagnoses
Psychotic experiences
The psychosis-like symptoms (PLIKS) semi-structured interview was
carried out at both 12 and 18 years. The content and reliability of the
interview has been described previously (Zammit et al., 2013), but
briefly, it covers the occurrence of hallucinations, delusions, and experi-
ences of thought interference, with ratings based on the Schedule for
Clinical Assessment in Neuropsychiatry. For this study, the primary out-
come was a binary definition of suspected or definite PEs at either age
12 or 18, versus no PEs at these ages.
Anxiety and depression
Binary variables for anxiety and depression were derived using scores
from the Computerized Interview Schedule—Revised (CIS-R), carried
out at 18 years (Lewis, Pelosi, Araya, & Dunn, 1992). This interview
establishes the type and severity of neurotic symptoms, and catego-
rizes depressive episodes according to ICD-10 criteria (including mild,
moderate, or severe depression). Anxiety was defined as the presence
of ICD-10 concordant diagnoses of generalized anxiety disorder, social
phobia, specific phobia, agoraphobia, or panic disorder, using the CIS-R
(Jones et al., 2016).
ASDs and traits
ASD diagnosis Diagnoses of ASD have been recorded in ALSPAC via
several methods, as described previously (Golding et al., 2017): all chil-
dren given a statement of special educational needs in the Avon area
were reviewed to identify those diagnosed as having ASD according to
ICD-10 criteria (Williams, Thomas, Sidebotham, & Emond, 2008).
FIGURE 1 Schematic of the QC process. A schematic of the QC
process overall, including the number of individuals and CNVs
retained after each step of filtering. Before QC, there were 150,657
CNVs and 7,572 subjects, and after QC, there were 22,037 CNVs
and 6,913 subjects (11,965 low-frequency [<1%] CNVs). After filter-
ing for those with no outcome data, 21,678 CNVs remained (11,750
low-frequency [<1%] CNVs), split among 6,807 subjects [Color figure
can be viewed at wileyonlinelibrary.com]
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Maternal reports were also used to source cases, according to responses
to the question (asked when children were 9 years): “Have you ever been
told that your child has autism, Asperger’s syndrome or autistic spectrum
disorder?.” Additional sources of cases included: children diagnosed by
age 16, due to classification by the educational system as requiring spe-
cial educational needs due to ASD; text responses to ALSPAC question-
naires relating to ASD diagnosis between 6 months and 11 years; and
finally, letters from parents to the ALSPAC study director.
ASD traits
Mean of seven ASD factors generated previously in ALSPAC Steer,
Golding, and Bolton (2010) report a factor analysis of 93 individual
measures related to ASD in ALSPAC. They generated seven factors. In
the current paper, the mean of these seven factors was used as a global
measure of ASD on a continuous scale. While initially very skewed, this
variable was readily transformable to approximate normality after
reflection and log-transformation (i.e., after transformation, a higher
TABLE 1 Summary of neuropsychiatric outcomes studied in this paper
Domain
Binary or
continuous? Trait (abbreviation)
Trait description/age at
measurement Measure Value
Total N
(max56,807)
Psychosis Binary Psychosis-like
symptoms (PEs)
Psychosis-like experiences recorded
(12 or 18 years)
N (% risk) 765 (16.9) 4,540
Depression
and anxiety
(Dep. & Anx.)
Binary Depression (Dep.) Symptoms meeting ICD-10 criteria
(18 years)
N (% risk) 244 (8.62) 2,830
Binary Anxiety (Anxiety) N (% risk) 292 (10.3) 2,830
Autism spectrum
disorders (ASDs)
Binary ASD diagnosis (ASD Dx) ASD diagnosis in ALSPAC N (% risk) 82 (1.2) 6,807
Continuous ASD traits (ASD F) Mean of seven ASD factors (Steer
et al., 2010) (lower5 favourable)
Mean (SD) 20.08 (0.33) 6,501
Continuous Sociability (EAS) REFLECTED (1-variable) Emotional-
ity, Activity and Sociability tem-
perament scale
(lower5 favourable)
(38 months)
Mean (SD) 217.2 (3.1) 5,283
Binary Repetitive behaviour (RB) Repetitive behaviour measure (di-
chotomized) at 69 months
N (% risk) 326 (6.89) 4,730
Binary Social communication
(SCDC)
Skuse social cognition score (di-
chotomized) at 91 months
N (% risk) 436 (9.35) 4,664
Binary Coherence (CCC) Child coherence scale (dichoto-
mized) at 9 years (108 months)
N (% risk) 452 (9.53) 4,742
ADHD
(Hyperactivity,
inhibition/impulse
control, attention)
Binary ADHD diagnosis
(ADHD Dx)
(pseudo-) ADHD diagnosis in AL-
SPAC
N (% risk) 90 (1.91) 4,714
Binary Hyperactivity score
(Hyperact.)
Symptom score for hyperactivity
(dichotomized) (81 months)
N (% risk) 487 (10.3) 4,715
Binary Inhibition and impulse
control (SSI [250])
Performance on Stop-Signal Inhibi-
tion task (250 millisecond [ms]
delay) (dichotomized)
(10 years)
N (% risk) 430 (9.95) 4,323
Binary Inhibition and impulse
control (SSI [150])
Performance on Stop-Signal Inhibi-
tion task (150 ms delay)
(dichotomized)
(10 years)
N (% risk) 375 (8.67) 4,323
Continuous Selective attention (log SS) Time (secs): “Sky Search” task (low-
er5 favourable) (8 years)
Median (IQR) 4.82 (4.1–5.76) 4,451
Continuous Attention control (log OW) Time (secs): “Opposite Worlds” task
(lower5 favourable) (8 years)
Median (IQR) 16.5 (14.5–19) 4,468
Cognition Continuous Phonological memory
(NWR) (–)
Score on non-word repetition task
(higher5 favourable) (8 years)
Mean (SD) 7.28 (2.51) 4,573
Continuous Working memory (DS) (–) Score on digit span task (high-
er5 favourable) (8 years)
Mean (SD) 13 (2.95) 4,452
Continuous Social cognition (NVR) (–) REFLECTED (1-variable) Number of
errors made on DANVA face
recognition (higher5 favourable)
(8 years)
Mean (SD) 23.56 (2.77) 4,190
Continuous IQ 8 (–) IQ score on WISC III (high-
er5 favourable) (8 years)
Mean (SD) 105 (16.3) 4,544
(–)5 lower score is indicative of reduced performance on these metrics (for all other traits, higher scores indicate a reduced performance, or the trait
has been dichotomized so that the risk group is coded as “1,” control group as “0”). Gray5 binary. White5 continuous. Abbreviations in this Table are
used in subsequent Tables/Figures.
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score is associated with ASD). Histograms of this variable before and
after transformation are shown in Supporting Information Figure 1.
Specific measures of ASD that predict ASD diagnosis in ALSPAC
Four ASD traits that have previously been noted to form a predictive
model of ASD in ALSPAC (pseudo-r2 reported as .48) (Steer et al.,
2010) were also used in this analysis. The coherence subscale of the
Children’s Communication Checklist (CCC), was scored at 9 years
(Bishop, 1998), and includes questions such as whether the child could
explain the rules of a simple game to a younger child. The Social and
Communication Disorders Checklist (SCDC, 91 months) (Sebat et al.,
2007) includes questions such as whether the child was able to realize
if they had offended people, and about whether they responded to
instructions. Another measure explained the presence of repetitive
behaviors (RB) at 69 months) (Rutter, Tizard, & Whitmore, 1971).
Finally, the sociability subscale of the Emotionality Activity and Soci-
ability (EAS) temperament scale included measures of whether the child
enjoyed the company of people at age 38 months (Buss & Plomin,
1984).
The RB and SCDC, CCC measures were highly skewed and were
therefore dichotomized, defining 10% of the sample for each group as
the “risk” group for ASD traits. The SCDC has previously been dicho-
tomized using a cutoff of 9 (Barona, Kothari, Skuse, & Micali, 2015),
and in this paper, the dichotomization method (using a 10% risk
group) supported a similar cutoff of 8. All traits were based on
responses to questionnaires filled out by mothers. The EAS was
approximately normally distributed, and thus was analyzed continu-
ously, after reflecting the variable, so that a higher score was associated
with increased risk of ASD. Histograms of these variables before and
after transformation are shown in Supporting Information Figure 2.
ADHD and associated traits
ADHD diagnosis ADHD diagnoses are recorded in ALSPAC according
to DSM-IV criteria, and based on the Development and Well-Being
Assessment at 91 months. This diagnosis variable was a composite of
children with combined, inattentive, or hyperactive-impulsive ADHD
diagnoses. Children with pervasive developmental disorders were
excluded.
FIGURE 2 Heatmap of phenotypic correlations between neuropsychiatric traits. This heatmap shows the correlations between all
outcomes studied, computed using the “mixed.cor” function provided in the R package “psych.” Pearson correlations are computed for pairs
of continuous variables, tetrachoric correlations for dichotomous variables (denoted with a “*”), and biserial correlations for mixed
pairs. Positive correlations are given in red, and negative correlations in blue, with intensity indicating the magnitude of the correlation.
(–)5 lower score is indicative of reduced performance on these metrics (for all other traits, higher scores indicate a reduced performance, or
the trait has been dichotomized so that the risk group is coded as “1,” control group as “0”). For expansion of abbreviations, see Table 1
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Hyperactivity Hyperactivity was assessed using the hyperactivity score
from the Strengths and Difficulties Questionnaire (Goodman, 1997).
This measure was derived from the results of a maternal questionnaire
administered when children were 81 months old, and provides a quan-
titative measure of ADHD that can also be used to generate a categori-
cal definition (Stergiakouli, Thapar, Davey Smith, & Pediatr, 2016).
Since the measure was zero-inflated in the participants included in this
study (see Supporting Information Figure 3), this variable was analyzed
as a dichotomous variable, defining a 10% risk group (equivalent to
using a cutoff of 7, as previously used in ALSPAC) (Stergiakouli et al.,
2016).
Inhibition and impulse control Inhibition and impulsivity were meas-
ured using the “Stop-Signal Inhibition” task (see Supporting Information
Methods) (Logan, 1994; Logan, Cowan, & Davis, 1984; Pindus et al.,
2015). The number of trials correct at the 250 ms delay and the 150
ms delay were used in this analysis. Both variables were dichotomized
into 10% risk groups, since they were negatively skewed, as shown in
Supporting Information Figure 4.
Attention Two measures of attention, capturing selective attention
and attentional control were used (both measured at 8 years), and
were assessed using the “Sky Search” and “Opposite Worlds” subtasks
of the Test of Everyday Attention for Children “TEACh” task (see Sup-
porting Information Methods) (Manly & Thames Valley Test Company,
1999). Both measures were log-transformed as this approximated a
better normal distribution (three observations on the selective atten-
tion measure were dropped to facilitate this). For both attentional
measures, a higher score indicates reduced attention, since the meas-
ures were based on response times. Histograms of these variables
before and after transformation are shown in Supporting Information
Figure 5.
2.4.2 | Neurocognitive traits
See Supporting Information Figure 6 for histograms of cognitive varia-
bles. All of these variables were analyzed continuously.
Memory
Working memory was assessed using the digit span subtest of the
Wechsler Intelligence Scale for Children (WISC), administered at 8
years (Wechsler, Golombok, & Rust, 1992). Phonological memory
was assessed using a nonword repetition task that was an adapta-
tion of a previously published task (Gathercole, Willis, Baddeley, &
Emslie, 1994). For both of these measures, a higher score indicates
better performance. See Supporting Information Methods for
details.
Social cognition
Social cognition (nonverbal recognition) was measured using the
number of errors made on the Diagnostic Analysis of Non-verbal
Accuracy (DANVA) face recognition task (Nowicki & Duke, 1994).
This variable was reflected before analysis, so that a higher score
indicates a better performance. See Supporting Information Meth-
ods for task details.
Intelligence quotient
IQ was measured at 8 years by the WISC (Wechsler et al., 1992). A
higher score indicates a higher IQ.
2.5 | Statistical analysis
All analyses were carried out using R. Analyses wherein the number of
subjects in a given cell was <5 were censored to protect confidential-
ity, concordant with ALSPAC policy (https://www.bristol.ac.uk/media-
library/sites/alspac/documents/alspac-publications-checklist.pdf).
2.5.1 | Transformations of phenotypes and covariates
Psychiatric diagnoses of PEs, anxiety, depression, ASD, and ADHD
were binary variables. Due to severe non-normality, many of the meas-
ures were dichotomized as detailed above. To summarize, the trans-
formed mean ASD factor score, the measures of cognition, and
attention were analyzed as continuous variables. Continuous outcomes
were standardized before analyses, to give mean50 and SD51. All
analyses were adjusted for sex and population ancestry, using the first
two principal components generated from the SNP genotype data used
to call CNVs.
2.5.2 | Genome-wide CNV burden
For all analyses, deletions and duplications were analyzed separately.
Effect sizes are presented as SD changes (continuous outcomes) and
log odds ratios (binary outcomes). In burden analyses, individuals carry-
ing one of the known pathogenic CNVs (described below) were
dropped (n585). Analyses retaining these subjects are available in the
Supporting Information.
Analyses were undertaken to assess CNV burden in several ways:
in the first analysis, the total number of genes affected by rare CNVs
(frequency <1%) was computed for each subject. This variable was
used as a measure of rare CNV burden, and each outcome was
regressed in turn against it, using either logistic or linear models for
binary and continuous outcomes, respectively. We also ran sensitivity
analyses, in which the main analysis was repeated, but with individuals
carrying known pathogenic CNVs retained.
In addition, we performed two other types of burden analyses,
relating to the length of CNVs carried. First, we computed the total
length (in kilobases, kb) of deletions and duplications of a frequency
<1% per subject. Next, based on the methods of Szatkiewicz et al.
(2014) and Männik et al. (2015), the length of the largest rare deletion
and duplication carried was noted for each individual. These variables
were then categorized into size: the reference group consisted of indi-
viduals carrying no rare (<1%) CNVs of >100 kb (or common CNVs
only). Three other categories were defined, in which the largest rare
CNV carried was >100 kb to 500 kb, >500 kb to 1 Mb, or >1 Mb.
These categories span the breadth of CNV sizes studied in two recent
papers of CNV burden in large cohorts (Männik et al., 2015; Szatkie-
wicz et al., 2014). For each outcome, presence of a CNV in each size
category was compared to the reference category.
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2.5.3 | Candidate CNVs analysis
A number of CNVs have been identified as being associated with SCZ
(Kendall et al., 2016). The association between presence of at least one
of these 12 rare CNVs (7 deletions, 5 duplications), and each outcome,
was assessed separately for deletions, duplications, and any CNV (see
Table 2). For the analysis assessing the effect of pathogenic deletions
only, those individuals carrying pathogenic duplications were dropped,
and vice versa. For coordinates of candidate CNVs, critical regions
(defined as stated in Kendall et al. [2016]), and criteria for defining
CNVs, see Table 3. To establish the presence or absence of these
CNVs, the package “bedtools” was used to compute overlaps between
observed CNVs and critical regions (Quinlan & Hall, 2010). For
neurexin-1 (NRXN1) deletions, exon coordinates were downloaded
from “TableBrowser” and according to transcript NM_004801 (Kent
et al., 2002). Results are summarized in Table 4.
2.5.4 | Multiple testing
Correlations between phenotypes were quantified using the “mixed.
cor” function of the “psych” R package (Revelle, 2015). Pearson correla-
tions are computed for pairs of continuous variables, tetrachoric corre-
lations for dichotomous variables, and biserial correlations for mixed
pairs. After computing the correlation matrix, the effective number of
tests were calculated using Nyholt’s “matSpDLite” method of spectral
decomposition. This method performs spectral decomposition of a cor-
relation matrix, and then examines the ratio of observed eigenvalue
variance to its possible maximum (Nyholt, 2004).
3 | RESULTS
3.1 | Descriptive statistics
3.1.1 | Correlations between phenotypes
Table 1 summarizes the descriptive data for the phenotypes studied,
including sample numbers, and the numbers in the risk group (for
binary/dichotomous outcomes) and means/medians (plus SDs and
IQRs) for continuous outcomes. Several of the phenotypes were cor-
related. Figure 2 shows a heat map of Pearson’s correlation coeffi-
cients between all outcome variables. As expected, the ASD and
ADHD measures showed correlations both between and within
groups. Anxiety and depression were also correlated with one
another (r5 .61), and moderately with PEs (r.35). Better perform-
ances on the cognitive measures were negatively related to the
majority of the psychiatric risk traits studied, but most strongly to
ASD and ADHD.
Nyholt’s method of spectral decomposition calculated that there
were 18 independent tests among all of the outcome variables studied
(Sterne & Davey Smith, 2001).
3.1.2 | CNVs
Table 2 summarizes the descriptive data for CNVs. 85/6,807 (1.25%)
individuals carried one or more of the 12 pathogenic CNVs (61 carried
a deletion, 24 carried a duplication) summarized in Table 3, and so
were excluded from the burden analyses, and descriptive data. Three
pathogenic CNVs were not observed in this particular study population:
the 7q11.23 duplication, the 15q11.2-q13.1 duplication, and the
22q11.2 deletion (Kendall et al., 2016). These CNVs were all observed
at frequencies of <0.01% in UK Biobank (n5151,169), so it is unsur-
prising that we did not observe them in our study population of
n56,807.
About 3,526/6,722 subjects in the burden analysis (52%) car-
ried no rare CNVs (deletions or duplications with frequency <1%)
greater than 100 kb in length. These individuals formed the refer-
ence category in the “largest carried” CNV burden analysis. The
median (IQR) length of rare deletions across the genome (36 kb [0–
131]) was greater than the median length of rare duplications (11
kb [0–136]). Large deletions were less common than large duplica-
tions when considering CNVs >500 kb, but >100 kb to 500 kb
deletions were slightly more common than duplications of the
same size.
FIGURE 3 Number of genes affected by rare CNVs in relation to neuropsychiatric traits. This analysis is a regression (logistic for binary
traits, linear for continuous traits) of the number of genes affected by rare CNVs (exposure) in relation to neuropsychiatric traits (outcome).
This is done separately for deletions (a) and duplications (b). For expansion of trait abbreviations, see Table 1. Other abbreviations: logOR|
SMD5 effect size (logOR for binary traits [denoted with a *], SD change for continuous traits); LCI/UCI5 lower and upper bounds of 95%
confidence interval; (–)5 lower score is indicative of reduced performance on these metrics (for all other traits, higher scores indicate a
reduced performance, or the trait has been dichotomized so that the risk group is coded as “1,” control group as “0”). All analyses were
adjusted for sex and population ancestry, using the first two principal components generated from the SNP genotype data used to call
CNVs
GUYATT ET AL. | 7
3.2 | Genome-wide CNV burden
3.2.1 | Total number of affected genes
There was evidence of increased risk of higher ASD scores on the
mean ASD factor (standardized mean difference [SMD] 0.021 [95%CI
0.010, 0.032], p51e-04), with increasing numbers of genes affected
by deletions. Weaker evidence of association (but concordant effect
sizes) with reduced cognitive performance on the IQ measure was also
observed (SMD20.023 [95%CI 20.037,20.009], p5 .002).
Among the binary and dichotomized traits, the majority of associa-
tions were consistent with the null effect, although confidence intervals
were wide, reflecting small sample sizes. Presence of increasing num-
bers of genes affected by rare deletions was associated with more
problems on the coherence measure (OR 1.06 [95%CI 1.02, 1.09],
p57e-04).
When the number of genes affected by rare duplications were
studied, there was weak evidence of an association with reduced
coherence (OR 1.04 [95%CI 1.02, 1.06], p53e-04), in addition to
stronger evidence of more ASD symptoms, according to the mean ASD
factor (SMD 0.018 [95%CI 0.011, 0.025], p53e-07). There was also
reduced performance (by about 0.01–0.02 SD units per gene affected
by rare duplications) on the measures of attentional control, as well as
phonological memory, working memory, and IQ (p< .001 for all traits).
For a graphical representation of this analysis, see Figure 3. For
sensitivity analyses in which carriers of known pathogenic CNVs were
retained, see Supporting Information Figure 7.
TABLE 2 Descriptive statistics of CNVs identified in ALSPAC, in relation to size, and overlap with genes, separately by deletions and
duplications
Number of individualsa carrying CNVs of given sizes N (deletions) N (duplications)
N (deletion|
duplication)
Rare CNVs (excluding individuals with at least one of 12 known pathogenic CNVsb)
Largest rare CNV 100 kb, or no rare CNVs (N) 4,942 4,817 3,526
[Largest rare CNV >100 kb (N)] 1,780 1,905 3,196
Largest rare CNV >100 kb to 500 kb (N) 1,646 1,521 2,688
Largest rare CNV >500 kb to 1 Mb (N) 88 271 351
Largest rare CNV >1 Mb (N) 46 113 157
Total number of subjects 6,722 6,722 6,722
Median length of rare CNVs in kb (IQR) 36 (0–131) 11 (0–136.1) 123 (29–304)
Median number of genes affected by rare CNVs 0 (0–1) 0 (0–1) 1 (0–3)
IQR5 interquartile range; kb5 kilobase; Mb5megabase; rare5 frequency <1%; SCZ5 schizophrenia.
aTotal N for whole paper56,807, N5 6,722 after excluding 85 carriers of pathogenic CNVs (61 deletion carriers, 24 duplication carriers).
bSee Table 3 for coordinates of these CNVs.
TABLE 3 Coordinates (hg19) of critical regions of 12 SCZ-associated CNVs
Chr* Start End Location Type Likely candidate gene(s) Criteria for defining this CNVb
chr1 146,527,987 147,394,444 1q21.1 Deletion . Size >50% of critical region
chr1 146,527,987 147,394,444 1q21.1 Duplication . Size >50% of critical region
chr2 50,145,643 51,259,674 2p16.3 Deletion NRXN1 Deletion of at least one exon
(NM_004801)
chr3 195,720,167 197,354,826 3q29 Deletion DLG1 Size >50% of critical region
chr7c 72,744,915 74,142,892 7q11.23 Duplication STX1A Size >50% of critical region
chr15 22,805,313 23,094,530 15q11.2 Deletion CYFIP1 Size >50% of critical region
chr15**c 23,561,268 28,390,339 15q11.2-q13.1 Duplication UBE3A and GABA receptor
gene cluster
Full critical region
chr15 31,080,645 32,462,776 15q13.3 Deletion . Size >50% of critical region
chr16 15,511,655 16,293,689 16p13.11 Duplication MYH11 Size >50% of critical region
chr16 21,950,135 22,431,889 16p12.1 Deletion UQCRC2 Size >50% of critical region
chr16 29,650,840 30,200,773 16p11.2 Duplication ALDOA, CORO1A,
MAPK3, TAOK2
Size >50% of critical region
chr22c 19,037,332 21,466,726 22q11.2 Deletion PI4KA, SEPT5 Size >50% of critical region
Chr5 chromosome.
aCoordinates taken from Supporting Information of Kendall et al., 2016 (except for **). For analyses, the liftOver tool was used to map from hg19 to
hg18 coordinates, specifying minimum ratio of bases that must remap as 0.95.
bSee Supporting Information Table S4 of Kendall et al. (2016).
cCNVs not observed in this study population.
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3.2.2 | Total length of rare CNVs
The associations for this analysis are generally similar to that of the
“number of genes” analysis, above, which may be explained by the fact
that the total length of rare CNV regions and the number of genes
affected by rare CNVs are correlated at r [Spearman]5 .76 (r
[Pearson]5 .64).
There was strongest evidence for an increase in total length of
deletions being associated with both an increase in the mean ASD fac-
tor, and a decrease in IQ at age 8. There was evidence for similar pat-
terns of association for the ASD factor for duplications.
See Supporting Information Figure 8 for graphical representations
of the association of increasing length of total rare deletions and dupli-
cations across the genome with the phenotypes studied. These analy-
ses excluded individuals carrying known pathogenic CNVs; Supporting
Information Figure 9 shows the results of the analysis in which carriers
of these known CNVs were retained.
3.2.3 | Largest CNV carried
Supporting Information Figures 10 and 11 shows the results of the
“largest, rare CNV carried” analysis for deletions and duplications,
respectively (in which individuals carrying known pathogenic CNVs
were excluded). Considering the burden of multiple testing (18 inde-
pendent tests), there was weak evidence of association between the
presence of large, rare deletions and more problems on the coherence
subscale of the CCC (OR for >500 kb to 1 Mb deletions: 2.82
[95%CI 1.38, 5.77], p5 .004). There was stronger evidence for associa-
tions among the continuous outcomes: presence of rare deletions
>500 kb was associated with more ASD symptoms, according to the
continuous measure of ASD, and with lower IQ. The effect sizes
between the >500 kb–1 Mb and >1 Mb deletions were broadly con-
sistent for the ASD measure and IQ, but for other measures (selective
attention, nonword repetition) there was most evidence for reduced
performances with presence of >500 kb to 1 Mb deletions. Large
duplications >1 Mb were associated with more ASD symptoms,
according to the continuous measure of ASD (SMD 0.32 [95%CI 0.14,
0.51], p56e-04).
Plots of analyses wherein individuals with any of the pathogenic
CNVs were retained (as a sensitivity analysis) are available in Support-
ing Information Figures 12 and 13 (for the deletion and duplication
analysis, respectively).
3.3 | Candidate CNV analysis
Since CNVs associated with SCZ may be related to other neurodeve-
lopmental traits (Kendall et al., 2016; Szatkiewicz et al., 2014), presence
of CNVs robustly associated with SCZ (Kendall et al., 2016; Rees et al.,
2014, 2016), was tested against the neuropsychiatric traits discussed.
These results are summarized in Table 4. There were insufficient case
numbers to assess the association between the pathogenic CNVs and
the four psychiatric variables (anxiety, depression, ASD, and ADHD), as
well as the repetitive behaviors and social communication trait.
The strongest association with candidate SCZ CNVs was observed
between general cognitive ability, as measured by IQ (SMD for
presence of any CNV [95%CI]: 20.508 [95%CI 20.778, 20.237],
p52e-04), with stronger evidence for deletions (SMD 20.617 [95%CI
20.936, 20.298], p52e-04), and no evidence of association with
duplications (SMD 20.233, [95%CI 20.740, 0.275], p50.369).
Weaker evidence of associations were observed between the candi-
date deletions (but not duplications) and the mean ASD factor (SMD
0.369 [95%CI 0.124, 0.614], p5 .003), as well as phonological memory
(SMD20.571 [95%CI 20.898, 20.243], p57e-04), and reduced social
cognition (–0.570 [95%CI 20.897, 20.243], p56e-04).
There was no strong evidence that the SCZ candidate CNVs were
associated with PEs in ALSPAC (OR 0.858 [95%CI 0.403, 1.827],
p5 .691), although confidence intervals were wide. There were insuffi-
cient cases to assess the effect of deletions and duplications separately.
The low numbers of cases for the dichotomized measure of attention
meant that power for these associations was low, but there was a trend
toward reduced attention being associated with presence of the patho-
genic CNVs.
Overall, these results provide some suggestion that the candidate
deletions for SCZ are associated with reduced cognition and ASD traits,
even after considering the number of comparisons made.
4 | DISCUSSION
This study sought to analyze the relationship between the burden of
rare copy number variation across the genome in relation to a wide
variety of neuropsychiatric phenotypes, measured in a young (<18
years), population-based cohort. The secondary aim was to examine
the association of known SCZ CNVs with these traits.
While there have been numerous studies of rare CNVs and neuro-
psychiatric conditions in relation to clinically ascertained cases (such as
SCZ [Grozeva et al., 2010; Kirov et al., 2009; Stone et al., 2008;
Szatkiewicz et al., 2014], BPD [Grozeva et al., 2010], and autism [Ching
et al., 2010; Glessner et al., 2009; Sebat et al., 2007]) and healthy con-
trols, the relationship in population-based samples is less well-studied.
We have prevoiusly found a relationship between the presence of rare
CNVs of increasing sizes and educational attainment in ALSPAC (Män-
nik et al., 2015), and a very recent study in a young Swedish population
also confirmed associations between presence of large CNVs and neu-
rodevelopmental problems (Martin et al., 2017). In line with this work,
an association in the current analysis was observed between IQ at 8
years and the number of genes affected by rare CNVs, as well as the
presence of rare deletions >500 kb. We also confirm that even in a
young, unselected population, it is still possible to detect associations
between genome-wide CNVs and neuropsychiatric traits, with the
association of a continuous measure of ASD also observed. Concordant
with observations reported an Icelandic sample (Stefansson et al.,
2014) and in UK Biobank, in which carriers of known pathogenic CNVs
had impaired performance on cognitive tests (Kendall et al., 2016), we
also observed associations between known SCZ CNVs and IQ, with
slightly weaker evidence of associations for the continuous measure of
ASD. When interpreting these results, it should be noted that there
was a moderate (r ﬃ –.3) negative correlation between the ASD/
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ADHD trait measures and IQ. It is therefore possible that the associa-
tions with the ASD/ADHD trait measures could be driven by larger
effect sizes in lower functioning subgroups of these individuals.
With the exception of a measure of coherence (which is also corre-
lated with IQ at 20.36), there were few clear associations observed
between presence of rare CNVs and the binary traits studied. This is
likely to be in part because there was less statistical power in these
analyses. In addition, general cognitive ability is associated with psychi-
atric disorders very broadly, which may explain why the deleterious
effect of CNV burden across the genome was observed most strongly
for IQ (Koenen et al., 2009).
The strengths and novelty of this work include the use of an unse-
lected population, and the use of measures that capture both clinical
and sub-threshold levels of psychopathology in a general population.
However, since for traits that were primarily ascertained by maternal
report (e.g., ASD traits), measurement error is more likely, and the
nature of the measurement error would determine the type of any sub-
sequent bias (i.e., if measurement error is related to CNV burden, then
this could affect associations in either direction, but if it is unrelated to
CNV burden, then the error would attenuate associations toward the
null). Nevertheless, using questionnaire or interview-based population-
based data is helpful, since it may be more readily attainable than clini-
cal records of psychiatric diagnoses, which are by their nature sensitive,
and require specific data linkage approval to be able to use and access
them. For ASD, we had access to both clinical and research measures
of ASD. Given that autism represents a spectrum, it is also possible
that the genetic architecture of clinical and subclinical diagnoses may
vary (as has been observed for psychosis) (Jones et al., 2016), in which
case studying these measures may not only be of value as a proxy but
as a means to understanding the genetic determinants of the “Broader
Autism Phenotype” (Losh, Childress, Lam, & Piven, 2008). There is
increasing evidence that ASD is heterogeneous, and that individual trait
measures may have distinct etiologies (Happe & Ronald, 2008). How-
ever, for ADHD, it has been observed that the genetic correlation of
ADHD as a disorder and ADHD traits approaches 1 (Demontis et al.,
2017), and there is also genetic correlation between ASD and its asso-
ciated traits (in ALSPAC [Robinson et al., 2016], and the Psychiatric
Genetics Consortium [Bralten et al., 2017]). This suggests that studying
ADHD/ASD traits in general populations is likely to be a powerful
method that will provide useful insights into these disorders.
The lack of association between PEs and CNVs is notable because
of the recent observation in ALSPAC that common genetic variation
predisposing to SCZ (a polygenic risk score) also showed no strong cor-
relation with PEs in this study (Jones et al., 2016). It has been sug-
gested that PEs in late childhood and adolescence may be more
strongly attributable to environmental factors, such as childhood
trauma and substance abuse, than to genetic predisposition to SCZ
(Jones et al., 2016). In addition to a lack of power, this could be another
explanation for the lack of association between CNVs and PEs in this
work. Other papers have also postulated that CNVs may modify the
psychosis phenotype: those with CNVs may be more likely to develop
SCZ, whereas those without may have a trajectory toward affective
disorders with psychotic symptoms. If the PEs measured in ALSPAC
are more representative of those with affective disorders than prodro-
mal features of SCZ, this could also explain the apparent lack of a clear
increased burden of rare CNVs among those with PEs (Grozeva et al.,
2010).
We considered the possibility of type I and type II error in our
results. The associations detected may be true positives, suggesting
that the presence of rare CNVs is truly associated with cognition and
ASD/ADHD traits in a general population. This fits with the results
from ALSPAC published previously as part of a replication effort to
study the relationship between CNVs and educational attainment in an
Estonian cohort (Männik et al., 2015) as well as with the results of a
large study of neurodevelopmental CNVs in relation to cognition in UK
Biobank (Kendall et al., 2016). However, it is also possible that at least
some of the associations are due to chance. Type I error was consid-
ered by computing the number of independent tests using a previously
validated method (Nyholt, 2004). Our strongest results (the association
of IQ and the composite ASD factor measure) are likely to be robust to
the number of comparisons made (18 tests, equivalent p-value for
alpha .05: p52.78e-03), but there is a greater possibility of false posi-
tives among the results for which there was weaker evidence. How-
ever, despite the possibility of multiple testing, the converse problem is
also possible: false negatives (type II error) are likely to have been a
problem for many of the binary traits, because of the relatively small
numbers in the risk groups.
Another important limitation of this study is the effect of attrition:
selective attrition, patterned by outcome may lead to dilution of effect
sizes (Wolke et al., 2009). In ALSPAC, a polygenic risk score for SCZ
has been found to be strongly associated with participant drop out,
indicating that individuals at risk for SCZ may be underrepresented in
ALSPAC. This may have an impact on statistical power, and may also
attenuate power in genetically correlated disorders, such as depression
and ADHD (Martin et al., 2016). This phenomenon might be explained
by common factors lying on the causal pathway between genetic risk
for SCZ, which could be responsible for attrition. Given that IQ was
found to be related to rare SCZ CNVs, and educational attainment is
known to be related to drop out in ALSPAC, this could be one mecha-
nism by which study children are lost to follow up (Boyd et al., 2013).
In addition, selection bias can be viewed as a collider, as participation in
a study may be a common effect of the exposures and outcomes being
studied. In this case, spurious correlations (“collider bias”) may be
induced between the genetic exposure and outcomes under study
(Martin et al., 2016; Munafo, Tilling, Taylor, Evans, & Davey Smith,
2016). This bias is likely to be worst when performing complete-case
analyses; since the analyses were not complete-case analyses (individu-
als were included if they had at least one CNV passing QC, all con-
founding variables, plus at least one—but not necessarily all—of the
outcomes), this may lessen the effect of collider bias on the results.
In conclusion, we have found some evidence of an association
between the burden of rare CNVs, IQ, and psychiatric traits in a
population-based cohort of UK children, and associations between can-
didate CNVs for SCZ and cognition. Having shown that CNV burden
and known SCZ CNVs are associated with these traits, a logical exten-
sion of this work could seek to map these associations to specific
GUYATT ET AL. | 11
regions of the genome using a hypothesis-free approach. The results
demonstrate the utility of studying population-based samples and non-
clinical outcomes to better understand the genetic architecture of cog-
nitive and psychiatric phenotypes.
ACKNOWLEDGEMENTS
We are extremely grateful to all the families who took part in this
study, the midwives for their help in recruiting them, and the whole
ALSPAC team, which includes interviewers, computer and laboratory
technicians, clerical workers, research scientists, volunteers, manag-
ers, receptionists, and nurses. GWAS data were generated by Sam-
ple Logistics and Genotyping Facilities at Wellcome Sanger Institute
and LabCorp (Laboratory Corporation of America) using support
from 23andMe. This publication is the work of the authors, who will
serve as guarantors for the contents of this paper. The UK Medical
Research Council (MRC) and the Wellcome Trust (Grant ref:
102215/2/13/2) and the University of Bristol provide core support
for ALSPAC. AG was funded by a Wellcome Trust PhD studentship:
102433/Z/13/Z. Further support for this work was funded by the
grant MR/M006727/1. The research was carried out in a MRC Unit
MC_UU_12013/8). JM was funded by the Wellcome Trust (Grant
No.: 106047). SZ is supported by the NIHR Biomedical Research
Centre at University Hospitals Bristol NHS Foundation Trust and the
University of Bristol. The views expressed in this publication are
those of the author(s) and not necessarily those of the NHS, the
National Institute for Health Research or the Department of Health.
CONFLICT OF INTEREST
TRG reports funding from Sanofi, Biogen, and GlaxoSmithKline for
projects unrelated to the work presented in this manuscript.
ORCID
Anna L. Guyatt http://orcid.org/0000-0003-1860-6337
REFERENCES
Barona, M., Kothari, R., Skuse, D., & Micali, N. (2015). Social communica-
tion and emotion difficulties and second to fourth digit ratio in a
large community-based sample. Molecular Autism, 6(1), 68.
Bishop, D. V. (1998). Development of the Children’s Communication
Checklist (CCC): A method for assessing qualitative aspects of com-
municative impairment in children. Journal of Child Psychology and
Psychiatry, 39(6), 879–891.
Boyd, A., Golding, J., Macleod, J., Lawlor, D. A., Fraser, A., Henderson, J.,
. . . Davey Smith, G. (2013). Cohort Profile: The “children of the
90s”–the index offspring of the Avon Longitudinal Study of Parents
and Children. International Journal of Epidemiology, 42(1), 111–127.
Bralten, J., van Hulzen, K. J., Martens, M. B., Galesloot, T. E., Arias Vas-
quez, A., Kiemeney, L. A., . . . Poelmans, G. (2017). Autism spectrum
disorders and autistic traits share genetics and biology. Molecular Psy-
chiatry, Nature Publishing Group. https://doi.org/10.1038/mp.2017.98
Bulik-Sullivan, B., Finucane, H. K., Anttila, V., Gusev, A., Day, F. R., Loh,
P.-R., . . . Neale, B. M. (2015). An atlas of genetic correlations across
human diseases and traits. Nature Genetics, 47(11), 1236–1241.
Buss, A. H., & Plomin, R. (1984). Temperament: Early developing personal-
ity traits. Hillsdale, NJ: L. Erlbaum Associates. 185 p.
Ching, M. S. L., Shen, Y., Tan, W.-H., Jeste, S. S., Morrow, E. M., Chen,
X., . . . Children’s Hospital Boston Genotype Phenotype Study Group.
(2010). Deletions of NRXN1 (neurexin-1) predispose to a wide spec-
trum of developmental disorders. American Journal of. Medical
Genetics Part B Neuropsychiatric Genetics, 153B, 937–947.
Demontis, D., Walters, R. K., Martin, J., Mattheisen, M., Als, T. D.,
Agerbo, E., . . . Neale, B. M. (2017). Discovery of the first genome-
wide significant risk loci for ADHD, https://doi.org/10.1101/145581
Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J.
K., Ramos-Quiroga, J. A., . . . Franke, B. (2015). Attention-deficit/
hyperactivity disorder. Nature Reviews Disease Primers, 1, 15020.
Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey
Smith, G., . . . Lawlor, D. A. (2013). Cohort profile: The avon longitudi-
nal study of parents and children: ALSPAC mothers cohort. Interna-
tional Journal of Epidemiology, 42(1), 97–110.
Gathercole, S. E., Willis, C. S., Baddeley, A. D., & Emslie, H. (1994). The
children’s test of nonword repetition. Memory, 2(2), 103–127.
Girirajan, S., Brkanac, Z., Coe, B. P., Baker, C., Vives, L., Vu, T. H., . . .
Eichler, E. E. (2011). Relative burden of large CNVs on a range of
neurodevelopmental phenotypes. PLoS Genetics, 7(11), e1002334.
Glessner, J. T., Wang, K., Cai, G., Korvatska, O., Kim, C. E., Wood, S., . . .
Hakonarson, H. (2009). Autism genome-wide copy number variation
reveals ubiquitin and neuronal genes. Nature, 459(7246), 569–573.
Golding, J., Ellis, G., Gregory, S., Birmingham, K., Iles-Caven, Y., Rai, D., &
Pembrey, M. (2017). Grand-maternal smoking in pregnancy and grand-
child’s autistic traits and diagnosed autism. Scientific Reports, 7, 46179.
Goodman, R. (1997). The Strengths and Difficulties Questionnaire: A
research note. Journal of Child Psychology and Psychiatry, and Allied
Disciplines, 38(5), 581–586.
Grozeva, D., Kirov, G., Ivanov, D., Jones, I. R., Jones, L., Green, E. K., . . .
Wellcome Trust Case Control Consortium. (2010). Rare copy number
variants: A point of rarity in genetic risk for bipolar disorder and
schizophrenia. Archives of General Psychiatry, 67, 318–327.
Guffanti, G., Torri, F., Rasmussen, J., Clark, A. P., Lakatos, A., Turner, J.
A., . . . Macciardi, F. (2013). Increased CNV-region deletions in mild
cognitive impairment (MCI) and Alzheimer’s disease (AD) subjects in
the ADNI sample. Genomics, 102(2), 112–122. https://doi.org/10.
1016/j.ygeno.2013.04.004
Happe, F., & Ronald, A. (2008). The “fractionable autism triad”: A review
of evidence from behavioural, genetic, cognitive and neural research.
Neuropsychology Review, 18(4), 287–304.
Jones, H. J., Stergiakouli, E., Tansey, K. E., Hubbard, L., Heron, J.,
Cannon, M., . . . Zammit, S. (2016). Phenotypic manifestation of
genetic risk for schizophrenia during adolescence in the general
population. JAMA Psychiatry, 73(3), 221–228.
Kendall, K. M., Rees, E., Escott-Price, V., Einon, M., Thomas, R., Hewitt,
J., . . . Kirov, G. (2016). Cognitive performance among carriers of
pathogenic copy number variants: Analysis of 152,000 UK Biobank
subjects. Biological Psychiatry, 82(2), 103–110.
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H.,
Zahler, A. M., & Haussler, D. (2002). The human genome browser at
UCSC. Genome Research, 12(6), 996–1006.
Kirov, G. (2015). CNVs in neuropsychiatric disorders. Human Molecular
Genetics, 24(R1), R45–R49.
Kirov, G., Grozeva, D., Norton, N., Ivanov, D., Mantripragada, K. K.,
Holmans, P., . . . O’donovan, M. C. (2009). Support for the involve-
ment of large copy number variants in the pathogenesis of schizo-
phrenia. Human Molecular Genetics, 18(8), 1497–1503.
12 | GUYATT ET AL.
Kirov, G., Pocklington, A. J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer,
D., . . . Owen, M. J. (2012). De novo CNV analysis implicates specific
abnormalities of postsynaptic signalling complexes in the pathogene-
sis of schizophrenia. Molecular Psychiatry, 17(2), 142–153. https://
doi.org/10.1038/mp.2011.154
Kirov, G., Rees, E., Walters, J. T. R., Escott-Price, V., Georgieva, L., Rich-
ards, A. L., . . . Owen, M. J. (2014). The penetrance of copy number
variations for schizophrenia and developmental delay. Biological Psychi-
atry, 75(5), 378–385. https://doi.org/10.1016/j.biopsych.2013.07.022
Koenen, K. C., Moffitt, T. E., Roberts, A. L., Martin, L. T., Kubzansky, L.,
Harrington, H., . . . Caspi, A. (2009). Childhood IQ and adult mental
disorders: A test of the cognitive reserve hypothesis. The American
Journal of Psychiatry , 166(1), 50–57.
Lewis, G., Pelosi, A. J., Araya, R., & Dunn, G. (1992). Measuring psychiat-
ric disorder in the community: A standardized assessment for use by
lay interviewers. Psychological Medicine, 22(2), 465–486.
Logan, G. D. (1994). On the ability to inhibit thought and action: A users’
guide to the stop signal paradigm. In D. Dagenbach & T. H. Carr
(Eds.), Inhibitory processes in attention, memory, and language
(pp. 189–239). San Diego, CA, US: Academic Press.
Logan, G. D., Cowan, W. B., & Davis, K. A. (1984). On the ability to
inhibit simple and choice reaction time responses: A model and a
method. Journal of Experimental Psychology. Human Perception and
Performance, 10(2), 276–291.
Losh, M., Childress, D., Lam, K., & Piven, J. (2008). Defining key features
of the broad autism phenotype: A comparison across parents of mul-
tiple- and single-incidence autism families. American Journal of Medi-
cal Genetics. Part B, Neuropsychiatric Genetics, 147B(4), 424–433.
Manly, T. & Thames Valley Test Company. (1999). TEA-Ch: The test of
everyday attention for children. Harcourt Assessment, 45. p.
Männik, K., Mägi, R., Mace, A., Cole, B., Guyatt, A. L., Shihab, H. A., . . .
Reymond, A. (2015). Copy number variations and cognitive pheno-
types in unselected populations. JAMA, 313(20), 2044–2054.
Martin, J., Cooper, M., Hamshere, M. L., Pocklington, A., Scherer, S. W.,
Kent, L., . . . Holmans, P. (2014). Biological overlap of attention-defi-
cit/hyperactivity disorder and autism spectrum disorder: Evidence
from copy number variants. Journal of the American Academy of Child
and Adolescent Psychiatry, 53(7), 761–770.e26. https://doi.org/10.
1016/j.jaac.2014.03.004
Martin, J., Tammimies, K., Karlsson, R., Lu, Y., Larsson, H., Lichtenstein,
P., & Magnusson, P. (2017). Copy number variation and neurodeve-
lopmental problems in females and males in the general population.
bioRxiv, 236042. https://doi.org/10.1101/236042
Martin, J., Tilling, K., Hubbard, L., Stergiakouli, E., Thapar, A., Smith, G.
D., . . . Davey Smith, G. (2016). Association of genetic risk for schizo-
phrenia with nonparticipation over time in a population-based cohort
study. American Journal of Epidemiology, 183(12), 1149–1158.
Morrow, E. M. (2010). Genomic copy number variation in disorders of
cognitive development. Journal of the American Academy of Child and
Adolescent Psychiatry, 49(11), 1091–1104.
Munafo, M. R., Tilling, K., Taylor, A. E., Evans, D. M., & Davey Smith, G.
(2016). Collider scope: How selection bias can induce spurious asso-
ciations. bioRxiv. https://doi.org/10.1101/079707
Nag, A., Bochukova, E. G., Kremeyer, B., Campbell, D. D., Muller, H.,
Valencia-Duarte, A. V., . . . Ruiz-Linares, A. (2013). CNV analysis in
Tourette syndrome implicates large genomic rearrangements in
COL8A1 and NRXN1. PLoS One, 8(3), e59061.
Nivard, M. G., Gage, S. H., Hottenga, J. J., van Beijsterveldt, C. E. M.,
Abdellaoui, A., Bartels, M., . . . Middeldorp, C. M. (2017). Genetic
overlap between schizophrenia and developmental psychopathology:
Longitudinal and multivariate polygenic risk prediction of common
psychiatric traits during development. Schizophrenia Bulletin, 43(6),
1197–1207.
Nowicki, S., & Duke, M. P. (1994). Individual differences in the nonverbal
communication of affect: The diagnostic analysis of nonverbal accu-
racy scale. Journal of Nonverbal Behavior, 18(1), 9–35.
Nyholt, D. R. (2004). A simple correction for multiple testing for single-
nucleotide polymorphisms in linkage disequilibrium with each other.
American Journal of Human Genetics, 74(4), 765–769.
O’Donovan, M. C., & Owen, M. J. (2016). The implications of the shared
genetics of psychiatric disorders. Nature Medicine, 22, 1214–1219.
Pindus, D. M., Davis, R. D. M., Hillman, C. H., Bandelow, S., Hogervorst,
E., Biddle, S. J. H., & Sherar, L. B. (2015). The relationship of
moderate-to-vigorous physical activity to cognitive processing in ado-
lescents: Findings from the ALSPAC birth cohort. Psychological
Research, 79(5), 715–728.
Plomin, R., & Deary, I. J. (2015). Genetics and intelligence differences:
Five special findings. Molecular Psychiatry, 20(1), 98–108.
Polderman, T. J. C., Benyamin, B., de Leeuw, C. A., Sullivan, P. F., van
Bochoven, A., Visscher, P. M., & Posthuma, D. (2015). Meta-analysis
of the heritability of human traits based on fifty years of twin stud-
ies. Nature Genetics, 47(7), 702–709.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R.,
Bender, D., . . . Sham, P. C. (2007). PLINK: A tool set for whole-
genome association and population-based linkage analyses. American
Journal of Human Genetics, 81(3), 559–575.
Quinlan, A. R., & Hall, I. M. (2010). BEDTools: A flexible suite of utilities
for comparing genomic features. Bioinformatics, 26(6), 841–842.
Redon, R., Ishikawa, S., Fitch, K. R., Feuk, L., Perry, G. H., Andrews, T. D.,
. . . Hurles, M. E. (2006). Global variation in copy number in the
human genome. Nature, 444(7118), 444–454.
Rees, E., Kendall, K., Pardi~nas, A. F., Legge, S. E., Pocklington, A., Escott-Price,
V., . . . Kirov, G. (2016). Analysis of intellectual disability copy number var-
iants for association with schizophrenia. JAMA Psychiatry, 73(9), 963.
Rees, E., Walters, J. T. R., Georgieva, L., Isles, A. R., Chambert, K. D.,
Richards, A. L., . . . Kirov, G. (2014). Analysis of copy number varia-
tions at 15 schizophrenia-associated loci. British Journal of Psychiatry,
204(2), 108–114. https://doi.org/10.1192/bjp.bp.113.131052
Revelle, W. (2015). psych: Procedures for Personality and Psychological
Research pp. 227–229, Northwestern University, Evanston, Illinois,
USA, http://CRAN.R-project.org/package=psych Version = 1.5.4
Ripke, S., Wray, N. R., Lewis, C. M., Hamilton, S. P., Weissman, M. M.,
Breen, G., . . . Sullivan, P. F. (2013). A mega-analysis of genome-wide
association studies for major depressive disorder. Molecular Psychia-
try, 18(4), 497–511.
Robinson, E. B., St Pourcain, B., Anttila, V., Kosmicki, J. A., Bulik-Sullivan,
B., Grove, J., . . . Daly, M. J. (2016). Genetic risk for autism spectrum
disorders and neuropsychiatric variation in the general population.
Nature Genetics, 48(5), 552–555.
Ronald, A., & Hoekstra, R. A. (2011). Autism spectrum disorders and
autistic traits: A decade of new twin studies. American Journal of
Medical Genetics Part B: Neuropsychiatric Genetics, 156(3), 255–274.
Ruderfer, D. M., Hamamsy, T., Lek, M., Karczewski, K. J., Kavanagh, D.,
Samocha, K. E., . . . Purcell, S. M. (2016). Patterns of genic intolerance
of rare copy number variation in 59,898 human exomes. Nature
Genetics, 48(10), 1107–1111.
Rutter, M., Tizard, J., & Whitmore, K. (1971). Education, health and
behaviour. Psychological Medicine, 1(5), 439 p.
Samson, J. N., & Wong, A. H. C. (2015). CHAPTER 1. The genetics of
schizophrenia. In Tatiana Lipina, John Roder (Eds.), Drug Discovery for
Schizophrenia (pp. 1–27), Cambridge: Royal society of chemistry.
GUYATT ET AL. | 13
Sandin, S., Lichtenstein, P., Kuja-Halkola, R., Larsson, H., Hultman, C. M., &
Reichenberg, A. (2014). The familial risk of autism. JAMA, 311(17), 1770.
Sebat, J., Lakshmi, B., Malhotra, D., Troge, J., Lese-Martin, C., Walsh, T.,
. . . Wigler, M. (2007). Strong association of de novo copy number
mutations with autism. Science, 316(5823), 445–449.
Steer, C. D., Golding, J., & Bolton, P. F. (2010). Traits contributing to the
autistic spectrum. PLoS One, 5(9), e12633.
Stefansson, H., Meyer-Lindenberg, A., Steinberg, S., Magnusdottir, B.,
Morgen, K., Arnarsdottir, S., . . . Stefansson, K. (2014). CNVs confer-
ring risk of autism or schizophrenia affect cognition in controls.
Nature, 505(7483), 361–366.
Stergiakouli, E., Martin, J., Hamshere, M. L., Langley, K., Evans, D. M., St
Pourcain, B., . . . Davey Smith, G. (2015). Shared genetic influences
between attention-deficit/hyperactivity disorder (ADHD) traits in
children and clinical ADHD. Journal of the American Academy of Child
and Adolescent Psychiatry, 54(4), 322–327.
Stergiakouli, E., Thapar, A., Davey Smith, G., & Pediatr, J. (2016). Associa-
tion of acetaminophen use during pregnancy with behavioral prob-
lems in childhood: Evidence against confounding. JAMA Pediatrics,
170(10), 964–970.
Sterne, J. A., & Davey Smith, G. (2001). Sifting the evidence-what’s
wrong with significance tests? BMJ, 322, 226–231.
Stone, J. L., O’donovan, M. C., Gurling, H., Kirov, G. K., Blackwood, D. H.
R., Corvin, A., . . . Visscher, P. M. (2008). Rare chromosomal deletions
and duplications increase risk of schizophrenia. Nature, 455(7210),
237–241.
Sullivan, P. F., Daly, M. J., & O’Donovan, M. (2012). Genetic architectures
of psychiatric disorders: The emerging picture and its implications.
Nature Reviews. Genetics, 13(8), 537–551.
Sullivan, P. F., Kendler, K. S., & Neale, M. C. (2003). Schizophrenia as a
complex trait. Archives of General Psychiatry, 60(12), 1187.
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000). Genetic epidemiol-
ogy of major depression: Review and meta-analysis. The American
Journal of Psychiatry, 157(10), 1552–1562.
Szatkiewicz, J. P., O’Dushlaine, C., Chen, G., Chambert, K., Moran, J. L.,
Neale, B. M., . . . Sullivan, P. F. (2014). Copy number variation in
schizophrenia in Sweden. Molecular Psychiatry, 19(7), 762–773.
Tansey, K. E., Rees, E., Linden, D. E., Ripke, S., Chambert, K. D., Moran,
J. L., . . . O’donovan, M. C. (2016). Common alleles contribute to
schizophrenia in CNV carriers. Molecular Psychiatry, 21(8), 1085–
1089.
Thapar, A., & Cooper, M. (2013). Copy number variation: What is it and
what has it told us about child psychiatric disorders?. Journal of the
American Academy of Child and Adolescent Psychiatry, 52(8), 772–774.
https://doi.org/10.1016/j.jaac.2013.05.013
Urraca, N., Cleary, J., Brewer, V., Pivnick, E. K., McVicar, K., Thibert, R.
L., . . . Reiter, L. T. (2013). The interstitial duplication 15q11.2-q13
syndrome includes autism, mild facial anomalies and a characteristic
EEG signature. Autism Research, 6(4), 268–279. https://doi.org/10.
1002/aur.1284
Wang, K., Li, M., Hadley, D., Liu, R., Glessner, J., Grant, S. F. A., . . .
Bucan, M. (2007). PennCNV: An integrated hidden Markov model
designed for high-resolution copy number variation detection in
whole-genome SNP genotyping data. Genome Research, 17(11),
1665–1674.
Wechsler, D., Golombok, S., & Rust, J. (1992). WISC-III UK Wechsler intel-
ligence scale for children (3rd ed.). Sidcup, UK: The Psychological
Corporation.
Williams, E., Thomas, K., Sidebotham, H., & Emond, A. (2008). Prevalence
and characteristics of autistic spectrum disorders in the ALSPAC
cohort. Developmental Medicine and Child Neurology, 50(9), 672–677.
Williams, N. M., Zaharieva, I., Martin, A., Langley, K., Mantripragada, K.,
Fossdal, R., . . . Thapar, A. (2010). Rare chromosomal deletions and
duplications in attention-deficit hyperactivity disorder: A genome-
wide analysis. Lancet, 376(9750), 1401–1408.
Wolke, D., Waylen, A., Samara, M., Steer, C., Goodman, R., Ford, T., &
Lamberts, K. (2009). Selective drop-out in longitudinal studies and
non-biased prediction of behaviour disorders. The British Journal of
Psychiatry, 195(3), 249–256.
Wray, N. R., & Gottesman, I. I. (2012). Using summary data from the Dan-
ish national registers to estimate heritabilities for schizophrenia, bipolar
disorder, and major depressive disorder. Frontiers in Genetics, 3, 118.
Zammit, S., Kounali, D., Cannon, M., David, A. S., Gunnell, D., Heron, J.,
. . . Lewis, G. (2013). Psychotic experiences and psychotic disorders
at age 18 in relation to psychotic experiences at age 12 in a longitu-
dinal population-based cohort study. American Journal of Psychiatry,
170(7), 742–750.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the sup-
porting information tab for this article.
How to cite this article: Guyatt AL, Stergiakouli E, Martin J,
et al. Association of copy number variation across the genome
with neuropsychiatric traits in the general population. Am J Med
Genet Part B. 2018;00:1–14. https://doi.org/10.1002/ajmg.b.
32637
14 | GUYATT ET AL.
